Litcius/Paper detail

A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis

Chunlei Zhang, Kexiang Yan, Qingchun Diao, Qing Guo, Hongzhong Jin, Sen Yang, Xiang Chen, Tiechi Lei, Jianhua Wu, Hong Yu, Min Zheng, Xing‐Hua Gao, Rodney Sinclair, Yi Zhu, Qian Xu, Jinhua Xu

2022Journal of the American Academy of Dermatology34 citationsDOI

Topics & Concepts

MedicineDose-ranging studyDouble blindedPlaceboMulticenter studyPlaque psoriasisPsoriasisAdverse effectDermatologyRandomized controlled trialInternal medicineDouble blindPathologyAlternative medicinePsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsDermatology and Skin Diseases
A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis | Litcius